Hypothesis

The size distribution of circulating mitochondrial DNA (mtDNA) fragments directly reports the functional state of mitochondrial nucleoids and predicts biological age independently of nuclear cfDNA methylation patterns.

Background

Nuclear cfDNA exhibits nucleosome‑protected fragmentation (~175 bp) that enables accurate chronological age prediction via methylation clocks【https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/】. In contrast, circulating mtDNA rises with age, acts as a DAMP that fuels inflamm‑aging【https://pubmed.ncbi.nlm.nih.gov/24470107/】, and its release links to mitochondrial quality‑control failure【https://pmc.ncbi.nlm.nih.gov/articles/PMC6103247/】. Nuclear loci regulate mtDNA copy number and heteroplasmy【https://www.nature.com/articles/s41586-023-06426-5】, yet no study has characterized mtDNA‑specific fragment size distribution within total cfDNA or tested its prognostic value.

Mechanistic Rationale

Mitochondrial nucleoids are organized by TFAM, mtSSB, and associated proteins that dictate DNA accessibility. When nucleoid packaging loosens—due to oxidative stress, impaired TFAM binding, or defective mitophagy—mtDNA becomes more susceptible to shear‑induced fragmentation during release into circulation. We propose that relaxed nucleoids yield a higher proportion of ultra‑short mtDNA fragments (<100 bp), whereas tightly packed nucleoids generate longer, protected fragments (150‑250 bp). This fragment‑size signature thus mirrors nucleoid integrity, which in turn reflects mitochondrial stress and downstream inflamm‑aging.

Predictions

1. Individuals with nucleoid‑loosening genotypes (e.g., variants in TFAM, LRPPRC, or mitophagy regulators) will show a shifted mtDNA cfDNA fragment profile toward shorter sizes, even after adjusting for chronological age.
2. The mtDNA fragment‑size score will correlate more strongly with phenotypic age markers (grip strength, inflammatory cytokines) than nuclear methylation age in cohorts over 60 years.
3. Experimental manipulation of nucleoid‑binding proteins in cultured cells will alter the released mtDNA fragment distribution in a predictable direction: TFAM knock‑down increases <100 bp fragments; TFAM over‑expression enriches 150‑250 bp fragments.

Experimental Design

• Human cohort: Collect plasma from 500 participants aged 40‑90. Measure nuclear cfDNA methylation age (48‑CpG clock) and mtDNA cfDNA fragment size distribution via targeted nanopore sequencing. Genotype participants for 92 nuclear loci known to regulate mtDNA【https://www.nature.com/articles/s41586-023-06426-5】.
• In vitro: Use CRISPRi to modulate TFAM, LRPPRC, and PINK1 in HEK293 cells. Induce mild mitochondrial stress (antimycin A low dose). Capture released cfDNA from supernatant and quantify fragment sizes using PCR‑free library prep.
• Statistical analysis: Build multivariate models testing whether mtDNA fragment‑size score adds predictive value for inflamm‑aging markers (IL‑6, TNF‑α) beyond nuclear methylation age. Interaction terms will test genotype‑phenotype effects.

Potential Outcomes

• Supportive: mtDNA fragment‑size score predicts cytokine levels and functional decline with β > 0.3 (p < 0.001) and remains significant after adjusting for nuclear age; genotype‑fragment associations replicate the directional predictions.
• Refutatory: No correlation between mtDNA fragment size and inflamm‑aging phenotypes; fragment distribution remains static across age and genotype, indicating that observed mtDNA cfDNA changes are driven solely by release quantity, not nucleoid state.

Falsifiability

The hypothesis is falsifiable if, across independent human cohorts and controlled cell‑culture experiments, mtDNA cfDNA fragment‑size distribution fails to (a) vary with nucleoid‑perturbing genotypes or manipulations, and (b) add explanatory power for age‑related functional decline beyond established nuclear methylation clocks. Demonstrating either null result would invalidate the proposed nucleoid‑state readout model.